Effects of levonorgestrel-releasing intrauterine system on lymphangiogenesis of adenomyosis

SiHyun Cho, Young Sik Choi, Bo Hyon Yun, Chon SJ, Seung Joo Chon, Jung YS, Yeon Soo Jung, Kim H, Hye Yeon Kim, HyeYeon Kim, Park JH, Joo Hyun Park, Seok Kyo Seo, Se Hoon Kim, Kim SH, Byung Seok Lee
American Journal of Clinical Pathology · 2015 · vol. 143(3) , pp. 352–361 · doi:10.1309/ajcpp8f4sfyfvxrn · PMID:25696793 · W2147114261
Observational OA: bronze CC0 ⤵ 8 in-corpus citations
📄 Open PDF View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-08 ⓘ

This study found that levonorgestrel-releasing intrauterine systems reduced lymphangiogenesis and lymphovascular density in the endometrial and myometrial tissues of adenomyosis patients compared to controls.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

OBJECTIVES: Lymphangiogenesis may be involved in the pathogenesis of adenomyosis. We investigated the lymphatic vessels of patients with adenomyosis, including those treated with levonorgestrel-releasing intrauterine system (LNG-IUS). METHODS: Full-thickness uterine samples were obtained from patients who received hysterectomies. Twenty-one patients with adenomyosis and 17 patients with adenomyosis who were treated with LNG-IUS were included. Eighteen patients with cervical intraepithelial neoplasia served as controls. Immunohistochemical staining was performed with antibodies against podoplanin and lymphatic vessel endothelial hyaluronan receptor 1. The lymphovascular density (LVD) was analyzed in each sample by the "hot spot" method. RESULTS: The LVDs were significantly higher in the endometrial and myometrial tissues of patients with adenomyosis compared with those of patients treated with the LNG-IUS or controls. No significant differences were noted between the LNG-IUS-treated group and controls. Evaluation of the LVDs according to the menstrual cycle showed that the differences in the endometrial tissues of the adenomyosis group and those of the LNG-IUS-treated group or the controls were more prominent during the secretory phase. CONCLUSIONS: Treatment with the LNG-IUS resulted in reduced lymphangiogenesis and LVD in the endometrial and myometrial tissues of patients with adenomyosis. Reduced lymphangiogenesis may be one mechanism by which the LNG-IUS reduces adenomyosis-related symptoms.

My notes (saved in your browser only)

Condition tags

adenomyosis

MeSH descriptors

Adenomyosis Intrauterine Devices, Medicated Levonorgestrel Lymphangiogenesis Adenomyosis Adenomyosis Adenomyosis Adult Adult Female Female Humans Humans Hysterectomy Hysterectomy Immunohistochemistry Immunohistochemistry Intrauterine Devices, Medicated Intrauterine Devices, Medicated Levonorgestrel

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (34)

Cited by (8)

Source provenance

europepmc
last seen: 2026-10-10T06:11:15.153948+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-08T21:15:04.544443+00:00
License: CC0 · commercial use OK